Grants and Contributions

Canada’s Strategy for Patient-Oriented Research (SPOR) is a national coalition of federal, provincial and territorial partners (patients and informal caregivers, provincial health authorities, health centres, charities, philanthropic organizations, private sector, etc.) dedicated to the integration of research into care. Its vision is that by 2025, Canada will have demonstrably improved health outcomes and enhanced the health care experience for patients through the integration of evidence at all levels of the health care system.

As outlined in the SPOR Patient Engagement Framework, patient-oriented research refers to a continuum of research that engages patients as partners, focusses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with relevant stakeholders, aims to apply the knowledge generated to improve healthcare systems and practices.
As a partner in SPOR, CIHR will provide bridge funding for fundable applications that are below the competition funding cut-off and aligned with the SPOR vision and the SPOR Patient Engagement Framework. Categories are described in the Funds Available section.

The objectives of Stream 1 are:
•Accelerate rapid research on SARS-CoV-2 variants in Canada to contribute to the national and global efforts to address SARS-CoV-2 variants; and
•Generate timely evidence on SARS-CoV-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

Stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:
1.The formation of a network (Stream 2) or participating in a network formed by another NPA (Stream 2); and,
2.The CIHR Network for Emerging Variants Research once established.

The objectives of Stream 1 are:
•Accelerate rapid research on SARS-CoV-2 variants in Canada to contribute to the national and global efforts to address SARS-CoV-2 variants; and
•Generate timely evidence on SARS-CoV-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

Stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:
1.The formation of a network (Stream 2) or participating in a network formed by another NPA (Stream 2); and,
2.The CIHR Network for Emerging Variants Research once established.

The specific objectives of this funding opportunity are:
• To provide recognition and funding to academic researchers;
• To provide a reliable supply of highly skilled and qualified researchers.

The objectives of Stream 1 are:
•Accelerate rapid research on SARS-CoV-2 variants in Canada to contribute to the national and global efforts to address SARS-CoV-2 variants; and
•Generate timely evidence on SARS-CoV-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

Stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:
1.The formation of a network (Stream 2) or participating in a network formed by another NPA (Stream 2); and,
2.The CIHR Network for Emerging Variants Research once established.

The objectives of Stream 1 are:
•Accelerate rapid research on SARS-CoV-2 variants in Canada to contribute to the national and global efforts to address SARS-CoV-2 variants; and
•Generate timely evidence on SARS-CoV-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

Stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:
1.The formation of a network (Stream 2) or participating in a network formed by another NPA (Stream 2); and,
2.The CIHR Network for Emerging Variants Research once established.

The objectives of Stream 1 are:
•Accelerate rapid research on SARS-CoV-2 variants in Canada to contribute to the national and global efforts to address SARS-CoV-2 variants; and
•Generate timely evidence on SARS-CoV-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

Stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:
1.The formation of a network (Stream 2) or participating in a network formed by another NPA (Stream 2); and,
2.The CIHR Network for Emerging Variants Research once established.

The objective is to invest in targeted COVID priority research areas from the Fall 2020 Project Grant competition such as vaccine hesitancy, pregnant women and children, racialized populations, Indigenous, confidence in science and SARS-CoV-2 variants.

• The CIHR HIV/AIDS Research Initiative (RI), managed by the CIHR Institute of Infection and Immunity (III), is responsible for the funding, management and oversight of research with a primary focus on HIV/AIDS and/or other STBBI (as identified in the Public Health Agency of Canada’s pan-Canadian STBBI framework for action). This includes, but is not limited to: human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV), chlamydia, gonorrhea, syphilis, and human papilloma virus (HPV). This funding is provided across all CIHR Research Themes : biomedical research, clinical research, health services research and social, cultural, environmental and population health research.
• Research that focuses on key populations identified by Canada’s pan-Canadian STBBI framework for action is highly encouraged.
• Information on the strategic directions of the CIHR HIV/AIDS Research Initiative can be found in the CIHR HIV/AIDS Research Initiative: Strategic Plan (2015-2020).

The objectives of Stream 1 are:
•Accelerate rapid research on SARS-CoV-2 variants in Canada to contribute to the national and global efforts to address SARS-CoV-2 variants; and
•Generate timely evidence on SARS-CoV-2 variants that will show impact within 3-6 months and is relevant to biological, clinical, health system, and public health strategies.

Stream 1 applicants are strongly encouraged to consider maximizing impact by outlining how they intend to participate in:
1.The formation of a network (Stream 2) or participating in a network formed by another NPA (Stream 2); and,
2.The CIHR Network for Emerging Variants Research once established.